The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

10 Oct 2007 07:01

Sopheon PLC10 October 2007 Embargoed Release: 07:00hrs Wednesday 10 October 2007 Sopheon Plc ('Sopheon') Leading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System The University Medical Center Utrecht Enhances Processes and Strengthens Position in Rapidly Expanding Trials Outsourcing Market Sopheon, the international software and services company, announced today thatthe University Medical Center (UMC) Utrecht, represented by its division theJulius Center, has selected Sopheon's Accolade product life cycle managementsystem to support its processes for conducting trials. Julius' research programis comprised of initiatives sponsored by leading pharmaceutical companies,universities and the government, including clinical investigations that involveother UMC divisions. Pharmaceutical companies are expected to increase spending for outsourced R&Dservices by almost 15% annually for the next five years. The core of thistrend is the outsourcing of clinical development, which more and morepharmaceutical executives see as a way to reduce costs and increase efficiency.The outsourced model also makes it possible to complete trials more quickly.The global growth in demand for outsourced clinical trial services is fuelingnew levels of business opportunity for independent research operations such asthe Julius Center. Julius is a particularly attractive alternative because ithas unique competencies in the management of complex, global clinical trialsinvolving multiple medical centers. More than 2,000 clinical trials are completed across UMC Utrecht each year, andJulius conducts or oversees a large portion of these investigations. Theadoption of Accolade will help the organization handle a steadily growing volumeof trial activity. Accolade provides an automated process structure that willenable the Center's research and program management staff to accelerate trialpreparation and execution. The system's data protection and managementcapabilities will contribute to ensuring trial security and quality, andfacilitate more efficient collaboration among researchers. Implementation ofthe system will also support compliance with European GCP (Good ClinicalPractice) directives for clinical trial execution. "As acceptance of the outsourced model for clinical trials management hasincreased among public and private organizations, our project pipeline hasbecome deeper and more complicated," said Robert Veen, data management managerfor the Julius Center. "Our deployment of Accolade has allowed us to takeproject data previously recorded and stored on isolated tools like spreadsheets,and consolidate them in a single, easily accessed repository. The flexibilityof the Accolade system, reflected in the fact that we can configure it on ourown, provides us with a platform that can accommodate multiple processes and anearly limitless range of specific process requirements. Accolade gives usconfidence that our trials will be executed consistently and with the kind ofrigorous quality control that will ensure the accuracy and reliability of theiroutcomes. Sopheon's solution will allow us to take the professionalization ofour research processes to a whole new level." "The University Medical Center Utrecht is an international symbol of excellencein scientific research and education," said Huub Rutten, Sopheon's vicepresident of research and development. "Their clinical trial operations are,like Sopheon and Accolade, focused on helping organizations get better productsto market faster. They have built their success on quality performance and anabiding commitment to the pursuit of best practices. We are proud to be able tocontribute even indirectly to the invention of the important new medicines andtreatments that result from their efforts." - Ends - Accolade(R) is a registered trademark of Sopheon plc. All other trademarks and registered trademarks are the sole property of their respective owners. About Julius Center Founded in 1996, the Julius Center for Health Sciences and Primary Care is partof the University Medical Center Utrecht. It carries out scientific research,provides education, and offers expertise and facilities in the area of clinicalhealth sciences, specializing in epidemiology, public health, general practice,nursing, dietary science, and medical technology assessment. The center has aleading and acquisitive position in the enlargement and dissemination ofknowledge, especially in the field of health sciences. This is done by means ofgroundbreaking research and by the provision of courses for researchers andclinicians. For more information, please visit the research section atwww.umcutrecht.nl About Sopheon Sopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. Sopheon'sAccolade system automates and governs the innovation process, enabling companiesto increase revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com For further information contact: Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735Arif Karimjee, CFOAndrew Tan Hansard Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.